387 related articles for article (PubMed ID: 22705248)
1. Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems.
Kratz F; Warnecke A
J Control Release; 2012 Dec; 164(2):221-35. PubMed ID: 22705248
[TBL] [Abstract][Full Text] [Related]
2. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy.
Luo C; Sun J; Sun B; He Z
Trends Pharmacol Sci; 2014 Nov; 35(11):556-66. PubMed ID: 25441774
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of serum proteins on drug delivery.
Kratz F; Elsadek B
J Control Release; 2012 Jul; 161(2):429-45. PubMed ID: 22155554
[TBL] [Abstract][Full Text] [Related]
4. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.
Kratz F
J Control Release; 2008 Dec; 132(3):171-83. PubMed ID: 18582981
[TBL] [Abstract][Full Text] [Related]
5. Prodrug strategies in anticancer chemotherapy.
Kratz F; Müller IA; Ryppa C; Warnecke A
ChemMedChem; 2008 Jan; 3(1):20-53. PubMed ID: 17963208
[TBL] [Abstract][Full Text] [Related]
6. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
7. Impact of albumin on drug delivery--new applications on the horizon.
Elsadek B; Kratz F
J Control Release; 2012 Jan; 157(1):4-28. PubMed ID: 21959118
[TBL] [Abstract][Full Text] [Related]
8. Extravasation of polymeric nanomedicines across tumor vasculature.
Danquah MK; Zhang XA; Mahato RI
Adv Drug Deliv Rev; 2011 Jul; 63(8):623-39. PubMed ID: 21144874
[TBL] [Abstract][Full Text] [Related]
9. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticles for drug delivery in cancer treatment.
Haley B; Frenkel E
Urol Oncol; 2008; 26(1):57-64. PubMed ID: 18190833
[TBL] [Abstract][Full Text] [Related]
11. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.
Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H
Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411
[TBL] [Abstract][Full Text] [Related]
12. Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug-drug conjugate for cancer therapy.
Huang P; Wang D; Su Y; Huang W; Zhou Y; Cui D; Zhu X; Yan D
J Am Chem Soc; 2014 Aug; 136(33):11748-56. PubMed ID: 25078892
[TBL] [Abstract][Full Text] [Related]
13. The application of prodrug-based nano-drug delivery strategy in cancer combination therapy.
Ge Y; Ma Y; Li L
Colloids Surf B Biointerfaces; 2016 Oct; 146():482-9. PubMed ID: 27400243
[TBL] [Abstract][Full Text] [Related]
14. Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs.
Fanciullino R; Ciccolini J; Milano G
Crit Rev Oncol Hematol; 2013 Dec; 88(3):504-13. PubMed ID: 23871532
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle technologies for cancer therapy.
Alexis F; Pridgen EM; Langer R; Farokhzad OC
Handb Exp Pharmacol; 2010; (197):55-86. PubMed ID: 20217526
[TBL] [Abstract][Full Text] [Related]
16. Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery.
Cheng R; Feng F; Meng F; Deng C; Feijen J; Zhong Z
J Control Release; 2011 May; 152(1):2-12. PubMed ID: 21295087
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticles for delivery of chemotherapeutic agents to tumors.
Vijayaraghavalu S; Raghavan D; Labhasetwar V
Curr Opin Investig Drugs; 2007 Jun; 8(6):477-84. PubMed ID: 17621878
[TBL] [Abstract][Full Text] [Related]
18. Liposomal cancer therapy: exploiting tumor characteristics.
Kaasgaard T; Andresen TL
Expert Opin Drug Deliv; 2010 Feb; 7(2):225-43. PubMed ID: 20095944
[TBL] [Abstract][Full Text] [Related]
19. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting.
Greish K
Methods Mol Biol; 2010; 624():25-37. PubMed ID: 20217587
[TBL] [Abstract][Full Text] [Related]
20. Tumor priming enhances delivery and efficacy of nanomedicines.
Lu D; Wientjes MG; Lu Z; Au JL
J Pharmacol Exp Ther; 2007 Jul; 322(1):80-8. PubMed ID: 17420296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
